Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 132

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 132
---
 17,983 18,838 Total revenues and other income167,133 131,314 196,245 Operating costs and expenses:Cost of Captisol11,074 10,512 52,827 Amortization of intangibles32,959 33,654 34,237 Research and development21,425 24,537 36,082 General and administrative78,654 52,790 70,062 Financial royalty assets impairment30,572 — — Fair value adjustments to partner program derivatives15,055 — — Total operating costs and expenses189,739 121,493 193,208       Gain on sale of Pelican— (2,121)— Operating income (loss) from continuing operations(22,606)11,942 3,037 Non-operating income and expenses:Gain from short-term investments75,024 46,365 28,540 Interest income8,055 7,711 2,046 Interest expense(3,037)(656)(1,799)Other non-operating (expense) income, net(54,918)(1,702)4,187 Total non-operating income, net25,124 51,718 32,974 Income before income tax from continuing operations2,518 63,660 36,011 Income tax expense(6,550)(9,841)(41,230)Net income (loss) from continuing operations(4,032)53,819 (5,219)Net loss from discontinued operations— (1,665)(28,142)Net income (loss):$(4,032)$52,154 $(33,361)Basic net income (loss) from continuing operations per share$(0.22)$3.11 $(0.31)Basic net loss from discontinued operations per share$— $(0.10)$(1.67)Basic net income (loss) per share$(0.22)$3.02 $(1.98)Shares used in basic per share calculation18,290 17,298 16,868 Diluted net income (loss) from continuing operations per share$(0.22)$3.03 $(0.31)Diluted net loss from discontinued operations per share$— $(0.09)$(1.67)Diluted net income (loss) per share$(0.